Serological assessment of gastric mucosal atrophy in gastric cancer

BMC Gastroenterology

Peter Malfertheiner¹  Doerthe Kuester²  Thomas Wex¹  Michael Selgrad¹  Jan Bornschein¹ 

[1] Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University of Magdeburg, Leipziger Str. 44, D-39120 Magdeburg, Germany;Department of Pathology, Otto-von-Guericke-University of Magdeburg, Leipziger Str. 44, D-39120 Magdeburg, Germany

关键词: cardia cancer;    pepsinogen;    gastrin;    glandular atrophy;    intestinal metaplasia;    Helicobacter pylori;    Gastric cancer;   

Others  :  1113145
DOI  :  10.1186/1471-230X-12-10

 received in 2011-09-29, accepted in 2012-01-31,  发布年份 2012

【 摘 要 】

Background

Non-invasive tools for gastric cancer screening and diagnosis are lacking. Serological testing with the detection of pepsinogen 1 (PG1), pepsinogen 2 (PG2) and gastrin 17 (G17) offers the possibility to detect preneoplastic gastric mucosal conditions. Aim of this study was to assess the performance of these serological tests in the presence of gastric neoplasia.

Methods

Histological and serological samples of 118 patients with gastric cancer have been assessed for tumor specific characteristics (Laurén type, localisation), degree of mucosal abnormalities (intestinal metaplasia, atrophy) and serological parameters (PG1, PG2, PG1/2-ratio, G17, H. pylori IgG, CagA status). Association of the general factors to the different serological values have been statistically analyzed.

Results

Patients with intestinal type gastric cancer had lower PG1 levels and a lower PG1/2-ratio compared to those with diffuse type cancer (p = 0.003). The serum levels of PG2 itself and G17 were not significantly altered. H. pylori infection in general had no influence on the levels of PG1, PG2 and G17 in the serum of gastric cancer patients. There was a trend towards lower PG1 levels in case of positive CagA-status (p = 0.058). The degree of both intestinal metaplasia and atrophy correlated inversely with serum levels for PG1 and the PG1/2-ratio (p < 0.01). Laurén-specific analysis revealed that this is only true for intestinal type tumors. Univariate ANOVA revealed atrophy and CagA-status as the only independent factors for low PG1 and a low PG1/2-ratio.

Conclusions

Glandular atrophy and a positive CagA status are determinant factors for decreased pepsinogen 1 levels in the serum of patients with gastric cancer. The serological assessment of gastric atrophy by analysis of serum pepsinogen is only adequate for patients with intestinal type cancer.

【 授权许可】

   
2012 Bornschein et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Schmidt N, Peitz U, Lippert H, Malfertheiner P: Missing gastric cancer in dyspepsia. Aliment Pharmacol Ther 2005, 1;21:813-820.
• [2]Yoshihara M, Hiyama T, Yoshida S, Ito M, Tanaka S, Watanabe Y, et al.: Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand J Gastroenterol 2007, 42:760-764.
• [3]Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S: Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006, 1;118:2315-2321.
• [4]Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y: Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006, 14;12:4873-4874.
• [5]Dan YY, So JB, Yeoh KG: Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006, 4:709-716.
• [6]Correa P: A human model of gastric carcinogenesis. Cancer Res 1988, 1;48:3554-3560.
• [7]Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P: H. pylori Infection Is a Key Risk Factor for Proximal Gastric Cancer. Dig Dis Sci 2010, 55:3124-31.
• [8]Kamada T, Hata J, Sugiu K, Kusunoki H, Ito M, Tanaka S, et al.: Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005, 1;21:1121-1126.
• [9]Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al.: Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007, 42(Suppl 17):21-27.
• [10]DiMario F, Moussa AM, Caruana P, Merli R, Cavallaro LG, Cavestro GM, et al.: 'Serological biopsy' in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scand J Gastroenterol 2003, 38:1223-1227.
• [11]Cao Q, Ran ZH, Xiao SD: Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007, 8:15-22.
• [12]Leja M, Kupcinskas L, Funka K, Sudraba A, Jonaitis L, Ivanauskas A, et al.: The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci 2009, 54:2377-2384.
• [13]Miki K: Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006, 9:245-253.
• [14]Miki K, Fujishiro M, Kodashima S, Yahagi N: Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009, 21:78-81.
• [15]Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoyama M, et al.: Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009, 12:158-163.
• [16]Mizuno S, Miki I, Ishida T, Yoshida M, Onoyama M, Azuma T, et al.: Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010, 55:3132-3137.
• [17]Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, et al.: Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer 2011, in press.
• [18]Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al.: Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005, 54:764-768.
• [19]Siewert J, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85:1457-1459.
• [20]Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20:1161-1181.
• [21]So JB, Yeoh KG, Moochala S, Chachlani N, Ho J, Wong WK, et al.: Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study. Gastric Cancer 2002, 5:228-232.
• [22]Capelle LG, de Vries AC, Haringsma J, Ter BF, de Vries RA, Bruno MJ, et al.: The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010, 71:1150-8.
• [23]Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De PG, et al.: Gastritis staging in clinical practice: the OLGA staging system. Gut 2007, 56:631-636.
• [24]Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Mernova VP, Polyakova MB: Possibility of non-invasive diagnosis of gastric mucosal precancerous changes. World J Gastroenterol 2004, 1;10:3146-3150.
• [25]Brenner H, Rothenbacher D, Weck MN: Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value. Int J Cancer 2007, 15;121:2782-2786.
• [26]Hattori Y, Tashiro H, Kawamoto T, Kodama Y: Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res 1995, 86:1210-1215.
• [27]Kikuchi S, Kato M, Katsuyama T, Tominaga S, Asaka M: Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter 2006, 11:147-151.
• [28]Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA: Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999, 44:693-697.
• [29]Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, et al.: Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 2005, 20;115:463-469.
• [30]Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, et al.: Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008, 17:838-845.
• [31]Kang JM, Kim N, Yoo JY, Park YS, Lee DH, Kim HY, et al.: The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008, 13:146-156.
• [32]Kwak MS, Kim N, Lee HS, Lee HE, Jung HC, Song IS: Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index. Dig Dis Sci 2010, 55:2275-2282.
• [33]Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, et al.: Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 2003, 15;63:2569-2577.
• [34]Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al.: Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007, 56:918-925.
• [35]Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, et al.: Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009, 58:636-642.
• [36]Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU: Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer 2006, 1;119:702-705.
• [37]Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, et al.: Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004, 3;96:388-396.
• [38]Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al.: Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008, 57:298-305.
• [39]Sun LP, Gong YH, Wang L, Yuan Y: Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China. World J Gastroenterol 2007, 28;13:6562-6567.
• [40]Rembiasz K, Konturek PC, Karcz D, Konturek SJ, Ochmanski W, Bielanski W, et al.: Biomarkers in various types of atrophic gastritis and their diagnostic usefulness. Dig Dis Sci 2005, 50:474-482.
• [41]Palli D, Masala G, Del GG, Plebani M, Basso D, Berti D, et al.: CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer 2007, 120:859-867.
• [42]Adamu MA, Weck MN, Rothenbacher D, Brenner H: Incidence and risk factors for the development of chronic atrophic gastritis: Five year follow-up of a population-based cohort study. Int J Cancer 2011, 1;128:1652-1658.
• [43]Con SA, Con-Wong R, Con-Chin GR, Con-Chin VG, Takeuchi H, Valerin AL, et al.: Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev 2007, 16:2631-2636.
• [44]Batista SA, Rocha GA, Rocha AM, Saraiva IE, Cabral MM, Oliveira RC, et al.: Higher number of Helicobacter pylori CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. BMC Microbiol 2011, 24;11:61.
• [45]Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, Rafiee R, Shahidi SM, Nikbin B, et al.: Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008, 6:174-179.
• [46]Xie XF, Ito M, Yoshihara M, Haruma K, Tanaka S, Chayama K: Serum pepsinogen levels in the Japanese population: prospective study of 9 years of follow-up. Hepatogastroenterology 2007, 54:1887-1890.
• [47]Abnet CC, Zheng W, Ye W, Kamangar F, Ji BT, Persson C, et al.: Plasma pepsinogens, antibodies against Helicobacter pylori, and risk of gastric cancer in the Shanghai Women's Health Study Cohort. Br J Cancer 2011, 26;104:1511-1516.
• [48]D'Elios MM, Appelmelk BJ, Amedei A, Bergmann MP, Del Prete G: Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004, 10;7:316-323.
• [49]Dinis-Ribeiro M, Areia M, deVries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al.: Management of precancerous conditions and lesions in the stomach (MAPS): guidelinefrom the European Society of Gatsrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012, 44:74-94.